Dr. Lal Path Labs Ltd. Earnings Summary — Q1 FY2027
Dr. Lal PathLabs Reports Strong Q1 Performance and Announces Strategic International Expansion
Quarterly Business Intelligence
AI Quarterly Scorecard™
Computed deterministically from the last 10 reported quarters.
Quarterly Business Momentum
- Revenue has increased for 3 consecutive quarters.
- Revenue of ₹798 Cr is 19.1% higher year-on-year.
- Revenue has compounded at 18.4% annualised over the last 10 quarters.
- Revenue is at its highest level in 10 quarters.
- Net profit has reached its highest level in 10 quarters.
- Net profit of ₹170 Cr is 28.0% above the same quarter last year.
- Profit growth is outpacing revenue growth, pointing to positive operating leverage.
- Net profit has compounded at 36.3% annualised across the period.
- Operating margin stands at 31.0% in Q1 FY2027.
- Operating margin expanded by 232 bps year-on-year.
- Over the last two years operating margin has expanded by 279 bps.
- PBT margin is 28.7%.
- Expense growth of 15.2% remained below revenue growth of 19.1%.
- Operating profit of ₹248 Cr is 28.7% higher year-on-year.
- Operating leverage continues to improve.
- 6 of the last 6 measured quarters delivered year-on-year revenue growth.
- Overall quarterly business momentum scores 84/100 (Strong) on the latest 10 quarters.
- Business momentum remains positive heading into the next quarter.
Quarterly Financials
Last 10 Reported Quarters • All figures in ₹ Crore • Margins in %
| Metric | Trend | Latest Q1 FY2027 | Q4 FY2026 | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q4 FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | Improving | 798 | 703 | 660 | 731 | 670 | 603 | 597 | 660 | 602 | 545 |
| Expenses | Improving | 550 | 516 | 481 | 507 | 478 | 434 | 443 | 458 | 432 | 401 |
| Operating Profit | Improving | 248 | 187 | 179 | 224 | 192 | 169 | 154 | 203 | 170 | 145 |
| Operating Margin | Stable | 31.0% | 26.6% | 27.2% | 30.7% | 28.7% | 28.1% | 25.8% | 30.7% | 28.2% | 26.5% |
| Other Income | Volatile | 32 | 24 | -6 | 25 | 28 | 26 | 25 | 22 | 21 | 18 |
| Interest | Accelerating | 6 | 6 | 7 | 5 | 5 | 5 | 5 | 6 | 6 | 7 |
| Depreciation | Stable | 44 | 45 | 42 | 41 | 35 | 36 | 36 | 35 | 35 | 37 |
| Profit Before Tax | Improving | 229 | 160 | 124 | 204 | 181 | 153 | 138 | 183 | 150 | 120 |
| Tax | Volatile | 58 | 28 | 33 | 51 | 47 | -2 | 40 | 52 | 42 | 34 |
| Net Profit | Improving | 170 | 131 | 91 | 151 | 132 | 155 | 97 | 129 | 106 | 85 |
| Net Margin | Improving | 21.3% | 18.7% | 13.7% | 20.6% | 19.8% | 25.7% | 16.2% | 19.6% | 17.7% | 15.5% |
Key Takeaways
- Revenue grew 19.1% YoY to ₹7,977 Mn, driven by expanding reach and scientific leadership initiatives.
- The Board approved an interim dividend of ₹5 per equity share (@ 50% on ₹10 face value).
- Acquired 100% stake in Mumbai-based Shahbazkers Diagnostic Centre for ₹200 Mn to fill micro-market gaps.
- Announced strategic entry into Ghana via 80% stake acquisition in Sunshine Healthcare Limited for up to GHS 45.6 Mn.
- Secured 30% stake in Neuome Technologies to gain access to innovative sample preservation and biobanking solutions.
- Swasthfit brand continues to be a major growth driver, contributing 27% to total revenue in the preceding fiscal year.
- The company effectively managed costs with Profit After Tax growing 27.2% YoY to ₹1,705 Mn.
- Granted 119,300 stock options under the 2025 RSU plan to eligible employees post-quarter end.
Management Guidance
Management is maintaining an outlook for 'early to mid-teens' revenue growth for FY27, backed by aggressive infrastructure expansion and infrastructure maturing. They expect to add 12-15 labs annually and anticipate maintaining EBITDA margins in the 27-28% range while reinvesting excess margins into growth initiatives.
Sentiment Shift
Improving
The company shows accelerating volume and realization trends, successfully integrating acquisitions while venturing into high-complexity testing and international markets.
Outlook
The outlook is robust as the company leverages its strong cash position of ₹1,526 Cr for M&A and digital infrastructure. Focus remains on 'AI-powered Precision Health Screening' via the Sovaaka brand and deepening penetration in Tier 3+ towns, which now contribute nearly 39% of revenue.
From the Annual Report (Key Quotes)
“The FY26 performance underscores the resilience of our business model and the continued preference towards clinically reliable organized diagnostic providers.”
“We are entering FY27 with strong operational momentum, a strengthened digital infrastructure, and a clear pathway towards sustaining early to mid-teens revenue growth.”
“Price hikes are not immediately on the cards as we wait and watch for competitive reactions to GST-related benefit pass-throughs.”
Official Quarterly Documents
Ask AI about this quarter
This summary is AI-generated from Dr. Lal Path Labs Ltd.'s latest quarterly filing and earnings call. For informational purposes only — not investment advice.